Welcome to our dedicated page for Walgreen Boots news (Ticker: WBA), a resource for investors and traders seeking the latest updates and insights on Walgreen Boots stock.
This page provides a focused view of news and announcements historically associated with Walgreens Boots Alliance, Inc. (formerly Nasdaq: WBA) and its related businesses, including Walgreens and Walgreens Specialty Pharmacy. Company communications highlight Walgreens as a U.S. retail pharmacy brand founded in 1901 that serves nearly 9 million customers and patients each day across approximately 8,500 stores in the U.S. and Puerto Rico, and Walgreens Boots Alliance as a pharmacy-led health and wellbeing enterprise formed through the combination of Walgreens and Alliance Boots.
News related to WBA and Walgreens has covered several key themes. One major area is corporate transactions and capital markets activity. In 2025, a series of announcements detailed the Agreement and Plan of Merger under which Blazing Star Merger Sub, Inc. merged with and into Walgreens Boots Alliance, Inc., resulting in the company becoming a wholly owned subsidiary of Blazing Star Parent, LLC, an affiliate of Sycamore Partners. Related releases described tender offers and consent solicitations for various series of Walgreens Boots Alliance and Walgreen Co. notes, pricing terms, extensions of expiration times and settlement dates, and the final results of these offers.
Another important news category involves the company’s transition from public to private ownership. A Form 8-K filed on August 28, 2025 describes the completion of the merger, the cash consideration and divested asset proceed rights received by shareholders, and the cessation of trading of WBA common stock and certain notes on Nasdaq. A subsequent Form 25 documents the removal of these securities from listing, and a Form 15 filed on September 8, 2025 terminates registration and suspends reporting obligations. Sycamore Partners separately announced the completion of its acquisition of Walgreens Boots Alliance, Inc. and its intention that Walgreens, The Boots Group, Shields Health Solutions, CareCentrix and VillageMD operate as standalone companies under private ownership.
Operational and healthcare-focused news also features prominently. Walgreens Specialty Pharmacy announced an expansion of its limited distribution drug network to 265 products, emphasizing its role in specialty medications for patients with rare, complex and chronic diseases and its independence from pharmacy benefit managers. Walgreens has also issued releases on vaccination services, including nationwide flu shot availability for individuals three years and older, walk-in and scheduled appointments, digital check-in features and incentives for myWalgreens members receiving vaccines.
Investors and observers using this news page can review historical coverage of WBA’s merger process, debt tender offers, governance and shareholder actions, as well as Walgreens’ specialty pharmacy initiatives and vaccination programs. For those tracking the evolution of the company, these articles collectively document WBA’s path from a publicly traded integrated healthcare and retail group to a privately held organization under Sycamore Partners, while also illustrating how Walgreens positions its pharmacies and specialty operations within the broader healthcare landscape.
Walgreens announces the launch of the 13th Annual Expressions art competition for high school students to promote creativity and self-expression. The competition, open until March 31, 2023, offers monetary prizes across four categories: visual arts, media arts, spoken word, and creative writing. With a commitment to mental health, Walgreens aims to help teens cope with challenges through artistic expression. Since its inception in 2009, the program has reached approximately one million students and awarded over $375,000 in prizes.
VillageMD has successfully completed the acquisition of Summit Health-CityMD on January 3, 2023 for $8.9 billion, expanding its capacity in primary, specialty, and urgent care services. This merger, supported by Walgreens Boots Alliance (WBA) and Cigna Corporation (CI), aims to enhance patient-centered care through a combined workforce of 20,000 professionals. The collaboration intends to leverage innovative healthcare delivery models across 680 locations in 26 markets, targeting improved health outcomes and value-based care.
Walgreens Boots Alliance (WBA) reported a first-quarter net loss of $3.7 billion, significantly impacted by a $6.5 billion opioid-related charge. Adjusted EPS fell 30.8% to $1.16. First-quarter sales decreased 1.5% year-over-year to $33.4 billion, with resilient core retail performance but challenges in COVID-19 vaccine sales. The company raised its full-year sales guidance to $133.5 billion to $137.5 billion, while maintaining adjusted EPS guidance of $4.45 to $4.65. Significant investments were made in U.S. Healthcare, particularly through the acquisition of Summit Health for $3.5 billion.
Walgreens Boots Alliance (WBA) will be represented by CEO Roz Brewer and CFO James Kehoe at the 41st Annual J.P. Morgan Healthcare Conference on January 10 at 11:15 a.m. PT in San Francisco. The conference will be webcasted live, accessible via WBA's investor relations website. With a heritage of 170 years, WBA operates approximately 13,000 locations across the U.S., Europe, and Latin America, focusing on integrated healthcare, pharmacy, and retail services. The company employs over 325,000 individuals and is committed to sustainability and community health.
Walgreens has expressed gratitude for the inclusion of the INFORM Consumers Act in the 2023 omnibus spending package. This bipartisan legislation aims to combat online sales of counterfeit and stolen products by increasing transparency and accountability in online marketplaces. The act mandates verification of high-volume sellers and enhances collaboration among law enforcement, manufacturers, and retailers. Walgreens, a leading pharmacy operator, supports this measure as part of its commitment to protect customers and combat retail theft.
Walgreens has launched rapid flu testing at over 5,000 pharmacies nationwide, utilizing Abbott's ID NOW devices to deliver results within two hours. This initiative aims to help communities manage the spread of respiratory illnesses during the peak holiday season, with flu activity reported at ten times last year's levels. The service allows individuals to get COVID-19 and flu tests in a single visit, enhancing accessibility to routine healthcare services.
Walgreens is enhancing last-minute holiday shopping with convenient 1-hour Delivery, 24-hour Delivery, and 30-minute Pickup options. Stores will operate on Christmas Eve and Christmas Day, offering flexible services for gift purchasing and health essentials. Customers can order from over 27,000 items for quick delivery, and same-day prescription delivery is available. With a diverse gift selection under $25, including toys and personal care items, Walgreens aims to meet festive shopping needs efficiently.
Walgreens Boots Alliance (WBA) will announce its fiscal 2023 first quarter results on January 5, 2023, at 7 a.m. ET. Following the results, a conference call with WBA management is scheduled for 8:30 a.m. ET and will be available for simulcast on WBA's investor relations website. A replay of the call can be accessed until January 12, 2023. WBA operates approximately 13,000 locations globally and is a trusted leader in healthcare and retail pharmacy, focusing on improving health access and delivering quality health services.
Walgreens Boots Alliance (WBA) has sold shares of AmerisourceBergen Corporation (ABC) for approximately $1.0 billion, with $0.8 billion from a Rule 144 sale and a $0.2 billion concurrent repurchase by AmerisourceBergen. WBA's ownership in ABC decreases from about 20% to 17%. Proceeds will primarily be allocated to debt reduction and funding strategic initiatives, particularly the acquisition of Summit Health-CityMD by VillageMD. WBA's long-term partnership with ABC remains unaffected.
Walgreens, in collaboration with DoorDash and Uber, has launched a program to offer free same-day delivery of Paxlovid, a COVID-19 antiviral therapy, to eligible patients across the U.S. With over 8,000 Walgreens locations participating, this initiative aims to enhance access for approximately 92% of the population, including those in underserved areas. The service responds to the increasing COVID-19 cases, with positivity rates reported at 36%. Eligible patients require a prescription to utilize this service, reinforcing Walgreens' commitment to addressing healthcare disparities.